Equities Analysts Issue Forecasts for NAMS Q3 Earnings

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) – Research analysts at HC Wainwright issued their Q3 2025 EPS estimates for NewAmsterdam Pharma in a note issued to investors on Monday, October 20th. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($0.31) per share for the quarter. HC Wainwright has a “Buy” rating and a $52.00 price target on the stock. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NewAmsterdam Pharma’s Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.33) EPS, FY2026 earnings at ($1.35) EPS, FY2027 earnings at $2.24 EPS, FY2028 earnings at $3.61 EPS and FY2029 earnings at $6.74 EPS.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.37. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. The company had revenue of $19.15 million during the quarter, compared to the consensus estimate of $1.44 million.

A number of other equities analysts also recently weighed in on NAMS. Royal Bank Of Canada raised their target price on shares of NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an “outperform” rating in a research note on Thursday, August 7th. Citigroup raised their target price on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Wednesday, October 8th. The Goldman Sachs Group started coverage on shares of NewAmsterdam Pharma in a research note on Thursday, July 17th. They set a “neutral” rating and a $27.00 target price for the company. Finally, Wells Fargo & Company started coverage on shares of NewAmsterdam Pharma in a report on Monday, August 25th. They set an “overweight” rating and a $45.00 price target on the stock. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $43.20.

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ NAMS opened at $35.00 on Wednesday. NewAmsterdam Pharma has a fifty-two week low of $14.06 and a fifty-two week high of $41.47. The company has a 50 day simple moving average of $28.51 and a two-hundred day simple moving average of $22.60. The company has a market capitalization of $3.94 billion, a price-to-earnings ratio of -21.60 and a beta of 0.02.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Frazier Life Sciences Management L.P. boosted its stake in shares of NewAmsterdam Pharma by 3.0% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock worth $300,754,000 after acquiring an additional 490,656 shares during the last quarter. RA Capital Management L.P. lifted its stake in shares of NewAmsterdam Pharma by 14.6% during the 1st quarter. RA Capital Management L.P. now owns 10,138,938 shares of the company’s stock valued at $207,544,000 after buying an additional 1,293,938 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of NewAmsterdam Pharma by 53.0% during the 1st quarter. Wellington Management Group LLP now owns 3,541,975 shares of the company’s stock valued at $72,504,000 after buying an additional 1,226,852 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in shares of NewAmsterdam Pharma by 54.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after buying an additional 1,062,359 shares in the last quarter. Finally, Woodline Partners LP lifted its stake in shares of NewAmsterdam Pharma by 0.5% during the 1st quarter. Woodline Partners LP now owns 2,442,397 shares of the company’s stock valued at $49,996,000 after buying an additional 11,615 shares in the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.

Insider Buying and Selling

In related news, Director James N. Topper bought 1,260 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The shares were bought at an average price of $24.99 per share, for a total transaction of $31,487.40. Following the completion of the acquisition, the director owned 3,027,864 shares of the company’s stock, valued at $75,666,321.36. This trade represents a 0.04% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $25.83, for a total transaction of $3,874,500.00. Following the transaction, the chief accounting officer owned 15,000 shares in the company, valued at $387,450. This represents a 90.91% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have purchased 2,391 shares of company stock worth $58,424 and have sold 226,342 shares worth $5,748,019. 20.84% of the stock is currently owned by corporate insiders.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.